4.6 Review

Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy

期刊

DRUG DELIVERY AND TRANSLATIONAL RESEARCH
卷 12, 期 5, 页码 1002-1016

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s13346-021-00995-6

关键词

RNA interference; siRNA; Cancer therapy; Gene knockdown; Gene silencing

向作者/读者索取更多资源

RNA interference has led to the development of siRNA-based therapeutics for gene therapy purposes, particularly in treating cancer. Despite the challenges associated with siRNA delivery systems, advancements have been made in targeted delivery methods using different types of materials.
Along with the evolutionary breakthrough of RNA interference and the applicability for gene knockdown, a subsequent development in siRNA-based therapeutics has been attained. The gene therapy based on RNAi is in transition progress from the research aspects to clinical base. Being a potent tool, siRNA is used as therapeutic against several disorders. Cancer which is one of the deadliest diseases is now treated with an advanced mechanism of siRNA delivery inside the genome, leading to gene silencing; thereby, blocking translation of gene to form protein. siRNA tool delivers remedial effects with the advantages of safe delivery and efficiency. Despite its merits, barriers including instability at physiological conditions, lack of ability to cross biological membranes, off-targets, and safety are also associated with siRNA delivery system. The gene silencing efficiency values both in vitro and in vivo reported in the past years have been reviewed by material type (lipid, polymer, silica, porous silicon, and metal). This review presents a deep insight in the development of targeted delivery of siRNA. Since several clinical trials have also been performed regarding the siRNA delivery against cancer, it can also be stated that the delivery system should be good enough to achieve effective siRNA drug development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据